Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Recruiting Phase 1 Trials for Tazemetostat (DB12887)

IndicationStatusPhase
DBCOND0153038 (Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05627245Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentTreatment